225 related articles for article (PubMed ID: 19343218)
21. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
22. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
23. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
24. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3 has not left an evolutionary footprint on the HIV-1 genome.
Ebrahimi D; Anwar F; Davenport MP
J Virol; 2011 Sep; 85(17):9139-46. PubMed ID: 21697498
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
[TBL] [Abstract][Full Text] [Related]
27. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
28. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
29. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
[TBL] [Abstract][Full Text] [Related]
30. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
Neogi U; Shet A; Sahoo PN; Bontell I; Ekstrand ML; Banerjea AC; Sonnerborg A
J Int AIDS Soc; 2013 Feb; 16(1):18472. PubMed ID: 23443042
[TBL] [Abstract][Full Text] [Related]
31. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
32. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
34. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
35. Mutation Vif-22H, which allows HIV-1 to use the APOBEC3G hypermutation to develop resistance, could appear more quickly in certain non-B variants.
Yebra G; Holguín A
J Antimicrob Chemother; 2011 Apr; 66(4):941-2. PubMed ID: 21393191
[No Abstract] [Full Text] [Related]
36. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
37. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
38. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G; Shindo K; Albin JS; Harris RS
Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
[TBL] [Abstract][Full Text] [Related]
39. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
40. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
